Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? Hosted by MarketBeat StaffNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9939 of 5 stars$785.95-3.2%0.66%84.97NVONovo Nordisk A/S4.3626 of 5 stars$105.35-1.5%0.68%34.09 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored7 Gene Editing Stocks Offering Transformational ChangeInvestors are talking about the impact that artificial intelligence (AI) can have on their portfolios. But the...MarketBeatMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored7 Retail Stocks to Buy for a Back-to-School SurgeAdvice like “skate where the puck is going" may sound like billboard investing, but there's a lot of tru...MarketBeatMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored13 Stocks With Strong Institutional BuyingHedge funds, university endowments, pension funds, and sovereign wealth funds have been pouring money into an ...MarketBeat Recent Videos Featured Articles and OffersTraders Are Flocking Back to Oil: What’s Fueling the OptimismNovember 19, 2024View Traders Are Flocking Back to Oil: What’s Fueling the Optimism2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareFrom Darwin(Ad)View 2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareDon't Miss a Second Chance to Buy These 2024 Winners for 2025November 20, 2024View Don't Miss a Second Chance to Buy These 2024 Winners for 2025Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?November 18, 2024View Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?3 Ultra-High Dividend Yield Stocks for the New YearNovember 18, 2024View 3 Ultra-High Dividend Yield Stocks for the New Year2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareFrom Darwin(Ad)View 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by MarketBeat StaffNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.9939 of 5 stars$785.95-3.2%0.66%84.97NVONovo Nordisk A/S4.3626 of 5 stars$105.35-1.5%0.68%34.09 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeatThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored7 Gene Editing Stocks Offering Transformational ChangeInvestors are talking about the impact that artificial intelligence (AI) can have on their portfolios. But the...MarketBeatMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored7 Retail Stocks to Buy for a Back-to-School SurgeAdvice like “skate where the puck is going" may sound like billboard investing, but there's a lot of tru...MarketBeatMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored13 Stocks With Strong Institutional BuyingHedge funds, university endowments, pension funds, and sovereign wealth funds have been pouring money into an ...MarketBeat
